Arteriosclerosis and Thrombosis, Vol 12, 250-255, Copyright © 1992 by American Heart Association

ARTICLES

Antithrombotic efficacy of low-molecular-weight heparin in deep arterial injury

M Heras, JH Chesebro, MW Webster, JS Mruk, DE Grill and V Fuster
Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minn 55905.

Low-molecular-weight heparin subfractions more specifically inhibit factor Xa than thrombin, and they may have advantages over unfractionated heparin in arterial thrombosis. The antithrombotic efficacy of four dosages of a low-molecular-weight heparin (CY216 at 100, 200, 400, or 500 Institute Choay units/kg) was compared with unfractionated calcium heparin (100 US Pharmacopeia units/kg) and placebo during deep arterial injury produced by balloon dilatation of the carotid artery in the pig. The acute thrombotic end points were 111In-labeled platelet and 125I-labeled fibrinogen/fibrin deposition and macroscopic mural thrombosis; these were related to the anti-factor Xa and antithrombin effects of the heparin preparations. Platelet deposition in segments with deep arterial injury was 42 +/- 28, 22 +/- 5, 29 +/- 12, 9 +/- 2, 9 +/- 2, and 11 +/- 3 x 10(6)/cm2 (mean +/- SEM) for pigs treated with placebo, with 100, 200, 400, and 500 units/kg CY216, and with 100 units/kg unfractionated heparin, respectively. Fibrinogen/fibrin deposition was 35 +/- 8, 19 +/- 2, 19 +/- 4, 21 +/- 3, 14 +/- 4, and 12 +/- 3 molecules x 10(12)/cm2, respectively; deposition was significantly reduced in pigs given 100 units/kg unfractionated heparin compared with placebo (p less than 0.05). Mural thrombosis was present in 74%, 45%, 30%, 14%, 5%, and 9% of deeply injured arterial segments, respectively (p = 0.02). Plasma anti-factor Xa activity and prolongation of the activated partial thromboplastin time (aPTT) with 100 units/kg unfractionated heparin were similar to that produced by 200 units/kg and 500 units/kg CY216, respectively. Thus, low-molecular-weight heparin, which predominantly inhibits factor Xa activity, was only moderately effective at reducing platelet thrombus deposition. It was less effective than 100 units/kg unfractionated heparin, except at high dosages, producing similar prolongation of the aPTT and the thrombin time.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				G. R. Upchurch Jr, G. N. Welch, J. E. Freedman, A. J. Fabian, A. Pigazzi, A. M. Scribner, C. S. Alpert, J. F. Keaney Jr, and J. Loscalzo High-Dose Heparin Decreases Nitric Oxide Production by Cultured Bovine Endothelial Cells Circulation, April 15, 1997; 95(8): 2115 - 2121. [Abstract] [Full Text]

				R. S. Schwartz, D. J. Holder, D. R. Holmes Jr, J. P. Veinot, A. R. Camrud, M. A. Jorgenson, and R. G. Johnson Jr Neointimal Thickening After Severe Coronary Artery Injury Is Limited by Short-term Administration of a Factor Xa Inhibitor : Results in a Porcine Model Circulation, April 15, 1996; 93(8): 1542 - 1548. [Abstract] [Full Text]

				J. S. Mruk, P. Zoldhelyi, M. W.I. Webster, M. Heras, D. E. Grill, D. R. Holmes Jr, V. Fuster, and J. H. Chesebro Does Antithrombotic Therapy Influence Residual Thrombus After Thrombolysis of Platelet-Rich Thrombus? : Effects of Recombinant Hirudin, Heparin, or Aspirin Circulation, February 15, 1995; 93(4): 792 - 799. [Abstract] [Full Text]